NCT03618550 2026-04-16
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Clinical Trials
15 trialsNCT04268277 2026-02-27
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
University of Ulm
Phase 2 Terminated
NCT03445858 2026-02-18
Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults
Children's Hospital Medical Center, Cincinnati
Phase EARLY_PHASE1 Completed
NCT03160079 2025-11-10
Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts
University of California, San Diego
Phase 1/2 Completed
NCT03179930 2025-07-23
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05313243 2025-03-20
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
Yale University
Phase 2 Recruiting
NCT05595447 2025-03-12
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
Hospital Regional de Alta Especialidad del Bajio
Phase 2/3 Recruiting
NCT03385226 2024-12-09
PORT
University College, London
Phase 2 Active not recruiting
NCT03630042 2024-11-07
PembroWM
University College, London
Phase 2 Completed
NCT03340766 2024-10-17
HARBOUR
Amgen
Phase 1 Completed
NCT02595866 2024-08-09
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT03349450 2023-11-02
SPiReL
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT03873025 2021-08-17
PLACARD
University College, London
Phase 1/2 Withdrawn
NCT03605589 2021-04-01
Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
Children's Hospital Medical Center, Cincinnati
Phase 1 Withdrawn
NCT04279938 2020-02-21
A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL
Royal Marsden NHS Foundation Trust
Phase 1 Withdrawn